PMA device
Alinity m HR HPV
Abbott Molecular, Inc. · Kit, Dna Detection, Human Papillomavirus (MAQ, Class III) · First FDA decision Nov 1, 2023, newest Jul 23, 2026Cervical cancer and HPV
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
0
Naming "Alinity m HR"
MAUDE reports
113
Brand "Alinity m HR", since 2015
PubMed studies
21
Mentioning "Alinity m HR"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Alinity m HR HPV
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- Alinity m HR HPVPMA supplement
P230003-S015 · Decided Jul 23, 2026 · 115 days after receipt · Normal 180 Day Track No User Fee
Device type: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS (MAQ) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Screening for Cervical Cancer with Human Papillomavirus (HPV) TestingNational analysisReview closedCAG-00442NUpdated Sep 22, 2026
- Screening for Cervical Cancer with Human Papillomavirus (HPV)National determinationOn the books210.2.1Updated Jun 17, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "Alinity m HR", any status and sponsor, newest update first.
No registered device study names "Alinity m HR".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Alinity m HR", and for the whole product code for context.
This brand
113 reports: 113 malfunction, 0 injury, 0 death
Whole product code MAQ
310 reports: 306 malfunction, 3 injury, 0 death
Newest reports for this brand
- Alinity m HR HPV AMP KitMalfunction
3005248192-2026-00099 · Received Oct 28, 2026 · Event dated Oct 12, 2026
Device type: Kit, Dna Detection, Human Papillomavirus (MAQ)
Device problem as coded: False Negative Result
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Abbott Alinity m HPV AMP Kit, used with the Alinity m System, product codes: a) REF 09N15-095; b) REF 09N15-090; c) REF 09N15-091Open, Classified
Z-0233-2025 · Started Sep 12, 2024 · Posted by FDA Oct 29, 2024
Reason given: Abbott has identified an increase of incidences regarding Error Code (EC) 9198 (Positive control is non-reactive) while using the Alinity m HR HPV AMP Kit and Alinity m STI AMP Kit. Certain invalidated positive assay controls can be traced to iron leaching into the Alinity m Lysis Solution from the lysis transfer pump...
Cause as FDA categorized it: Device Design · Device type: Kit, Dna Detection, Human Papillomavirus (MAQ)
Published research
The most relevant PubMed records for "Alinity m HR"[tiab]. The summary above synthesizes these.
- Clinical Accuracy of Alinity m HR HPV Assay on Self- versus Clinician-Taken Samples Using the VALHUDES Protocol.
Latsuzbaia A, Van Keer S, Vanden Broeck D, et al. · J Mol Diagn · 2023Research Support, Non-U.S. Gov't
- Performance of the Alinity m HR HPV assay on self-collected vaginal samples compared to clinician-collected cervical samples.
Tsegaye AT, Clarke MA, Long B, et al. · J Clin Virol · 2025Comparative Study, Evaluation Study
- Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
O¡trbenk Valenčak A, terbenc A, Seme K, et al. · J Clin Microbiol · 2019Research Support, Non-U.S. Gov't
- Alinity m HR HPV Assay: United States Clinical Trial Design and High-Risk Human Papillomavirus Prevalence.
Stoler M, Cullum R, Lucic D, et al. · J Low Genit Tract Dis · 2025
- 2020 list of human papillomavirus assays suitable for primary cervical cancer screening.
Arbyn M, Simon M, Peeters E, et al. · Clin Microbiol Infect · 2021Meta-Analysis, Systematic Review
- Comparative clinical performance of Alinity m HR HPV, cobas 4800 HPV, and cobas 6800 HPV for cervical cancer screening.
Huang S, Gentil LG, Schmidt C, et al. · Microbiol Spectr · 2025Comparative Study, Evaluation Study
- Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.
Dhillon SK, O¡trbenk Valenčak A, Xu L, et al. · J Clin Microbiol · 2021Research Support, Non-U.S. Gov't
- Prevalence and significance of HPV DNA detection below the clinical threshold of the commercial kit Alinity m HR-HPV assay (Abbott).
Node J, Dor F, Puget L, et al. · J Med Virol · 2024
- Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening.
Heideman DAM, O¡trbenk Valenčak A, Doorn S, et al. · Viruses · 2022Research Support, Non-U.S. Gov't
- Multi-center evaluation of the Alinity m HR HPV assay with liquid-based cytology cervical specimens in the United States.
Goldstein DY, Yang T, Lucic D, et al. · Microbiol Spectr · 2025Multicenter Study, Evaluation Study
- Application of CytoPath®Easy Vials in Cervical Cancer Screening: Self-Sampling Approach.
Fernandes SPM, Vilarinho AS, Frutuoso A, et al. · J Cytol · 2024
- Clinical and Analytical Evaluation of the Abbott Alinity m HR HPV Assay in a New Generation First-Void Urine Collector.
Van Keer S, Téblick L, Donders G, et al. · J Med Virol · 2025Clinical Trial, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code MAQ.
- cobas HPVRoche Molecular Systems, Inc. · PMA 2026
- BD Onclarity HPV Assay Reagent Pack (SKU 444075) and BD COR HPV Extraction Trough (SKU 444074)Becton, Dickinson and Company · PMA 2026
- Digene Hybrid Capture 2 (HC2) Hpv Dna TestsQiagen Gaithersburg, Inc. · PMA 2015
- Cervista Hpv Hr and Genfind KitHologic, Inc. · PMA 2014
- Cervista Hpv 16/18Hologic, Inc. · PMA 2014
- Onclarity HPV AssayBecton, Dickinson and Company · PMA 2025
- Digene HC2 High Risk Hpv Dna Test and Digene HC2 Hpv Dna TestQiagen Gaithersburg, Inc. · PMA 2014
- Digene Hybrid CAPTURE2Qiagen Gaithersburg, Inc. · PMA 2009
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.